Natera Drops After FDA Issues Warning About Prenatal Screenings

Natera shares fell as much as 4% in intraday trading after the Food and Drug Administration issued a warning about the possibility of false results from prenatal screening tests.

• The FDA issued a warning about “the risks of false results with genetic non-invasive prenatal screening (NIPS) tests, sometimes called noninvasive prenatal testing or tests (NIPT)”
• “The FDA is aware of cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy”
• A NIPS test is yet to be authorized, cleared or approved by the FDA
• Shares fell as
• Natera’s average ...